Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies
A Multiple-center Phase II Study to Evaluate the Clinical Outcome of Reduced Conditioning Regimen With Melphalan, Busulfan and Fludarabine for Patients >=55 Years With Myeloid Malignancies.
Shanghai Jiao Tong University School of Medicine
61 participants
Jun 1, 2022
INTERVENTIONAL
Conditions
Summary
In this multiple-center phase II study, the aim is to evaluate the clinical outcome of reduced intensity conditioning regimen with fludarabine (150mg/m2), busulfan (6.4mg/kg) and melphalan (100mg/m2) in patients with myeloid malignancies including AML, MDS and CMML \>=55 years.
Eligibility
Inclusion Criteria4
- Age 55-65
- patients with HLA-matched sibling donors, 9-10/10 matched unrelated donors or haplo-identical donors.
- patients with AML in remission, or MDS in any stage, or CMML in any stage
- inform consent provided
Exclusion Criteria2
- patients with abnormal liver (>3N), renal (1.5N) or cardiac function
- patients with active infection
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Reduced intensity conditioning regimen with fludarabine, busulfan and melphalan
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05436561